Effect of rosuvastatin combined with sodium tanshinone Ⅱ A sulfonate on blood lipids,cardiac function and serum inflammatory factors in elderly patients with stable angina pectoris and hyperlipidemia
10.3969/j.issn.1008-0074.2025.03.07
- VernacularTitle:瑞舒伐他汀联合丹参酮ⅡA磺酸钠治疗对老年稳定型心绞痛合并高脂血症患者血脂、心功能及血清炎症因子水平的影响
- Author:
Shu-guang WANG
1
;
Xiu LI
1
;
Wen-tao MA
1
Author Information
1. 聊城市第三人民医院心内科,山东聊城 252000
- Publication Type:Journal Article
- Keywords:
Angina,stable;
Aged;
Hyperlipidemias
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2025;34(3):317-322
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the effect of rosuvastatin combined with sodium tanshinone Ⅱ A sulfonate(STS)on blood lipids,cardiac function and serum inflammatory factors in elderly patients with stable angina pectoris(SAP)and hyperlipidemia(HLP).Methods:This randomized controlled study enrolled 140 elderly patients with SAP and HLP admitted in the Third People's Hospital of Liaocheng between December 2021 and December 2023.Patients were divided into control group(n=70,took rosuvastatin orally)and combination group(n=70,treated with ro-suvastatin combined with STS).Both groups were treated for two weeks.Clinical effects,blood lipids,cardiac function and serum inflammatory factors and incidence of adverse reactions were compared between the two groups.Results:Total effective rate of combination group was significantly higher than that of control group(92.86％vs.80.00％,P=0.026).Compared with patients in control group,those in combination group had significant lower triglyceride(TG)[(1.42±0.39)mmol/L vs.(1.69±0.11)mmol/L],total cholesterol(TC)[(4.37±0.69)mmol/L vs.(5.25±0.43)mmol/L]and low density lipoprotein-cholesterol(LDL-C)[(2.62±0.39)mmol/L vs.(3.19±0.38)mmol/L],and significant higher high-density lipoprotein cholesterol(HDL-C)[(1.24±0.31)mmol/L vs.(1.10±0.22)mmol/L](P＜0.01 all).Compared with patients in control group,those in combination group had significant higher left ventricular ejection fraction(LVEF)[(59.13±5.46)％vs.(55.97±4.02)％,P＜0.001],and significant lower C-reactive protein(CRP)[(2.66±0.68)mg/L vs.(3.50±1.61)mg/L],tumor necrosis factor-α(TNF-α)[(93.34±19.26)pg/ml vs.(111.70±25.00)pg/ml]and interleukin-6(IL-6)[(76.28±23.88)pg/ml vs.(100.64±27.52)pg/ml](P＜0.001 all).There was no significant difference in the total incidence rate of adverse reactions between two groups(25.7％vs.14.3％,P=0.091).Conclusion:Rosuvas-tatin combined with STS is effective in the treatment of elderly patients with SAP and HLP.It is superior to rosuvas-tatin alone in terms of improving blood lipids,cardiac function and serum inflammatory factors.
